Market accessOfficial

CMS publishes final rule CMS-4215-F on Medicare drug price negotiation and Part D

🇺🇸 CMS · Thu 05 Nov 2026

The US Centers for Medicare & Medicaid Services has issued a final rule covering both the Medicare Drug Price Negotiation Program and the Medicare Prescription Drug Benefit Program.

The US Centers for Medicare & Medicaid Services (CMS) has published a final rule, designated CMS-4215-F, that addresses the Medicare Drug Price Negotiation Program and the Medicare Prescription Drug Benefit Program. The item is dated 5 November 2026.

The material available to VigiEye gives only the title of the rule. It does not describe the specific provisions, any changes from earlier proposals, or timelines for implementation, so these cannot be reported here.

By way of context, the Medicare Drug Price Negotiation Program is the mechanism under which CMS negotiates prices for selected Medicare drugs. The Medicare Prescription Drug Benefit Program is the Part D outpatient drug coverage administered through private plans. A rule spanning both programmes bears on drug pricing and on how Part D benefits are run.

Companies and plan sponsors will need the full rule text to establish what, if anything, changes for them.

What it means for your team

  • Market access and pricing teams should obtain the full text of CMS-4215-F and check which provisions affect their products and Part D contracting.
  • The supplied title does not reveal the substance, so internal impact assessments should wait until the rule has been read in full.
  • Teams with products in or near the Medicare negotiation process should confirm any procedural or timing implications directly from the rule.

Official source: CMS ↗

Article written by VigiEye from the official source (CMS). AI-assisted; check the source before acting.

More Market access All →